cortodoxone and Alopecia

cortodoxone has been researched along with Alopecia* in 3 studies

Reviews

1 review(s) available for cortodoxone and Alopecia

Article	Year
Clascoterone: First Approval. Drugs, 2020, Volume: 80, Issue:16 Clascoterone (Winlevi Topics: Acne Vulgaris; Administration, Topical; Alopecia; Androgen Receptor Antagonists; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cortodoxone; Dose-Response Relationship, Drug; Drug Approval; Germany; Humans; Multicenter Studies as Topic; Propionates; Randomized Controlled Trials as Topic; Receptors, Androgen; Skin; Skin Cream; Solutions; United States; United States Food and Drug Administration	2020

Article

Year

Drugs, 2020, Volume: 80, Issue:16

Clascoterone (Winlevi

Topics: Acne Vulgaris; Administration, Topical; Alopecia; Androgen Receptor Antagonists; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cortodoxone; Dose-Response Relationship, Drug; Drug Approval; Germany; Humans; Multicenter Studies as Topic; Propionates; Randomized Controlled Trials as Topic; Receptors, Androgen; Skin; Skin Cream; Solutions; United States; United States Food and Drug Administration

2020

Other Studies

2 other study(ies) available for cortodoxone and Alopecia

Article	Year
Clascoterone as a novel treatment for androgenetic alopecia. Clinical and experimental dermatology, 2020, Volume: 45, Issue:7 Topics: Alopecia; Cortodoxone; Dihydrotestosterone; Hair Follicle; Humans; Propionates; Testosterone	2020
Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro Journal of drugs in dermatology : JDD, 2019, Feb-01, Volume: 18, Issue:2 Cortexolone 17α-propionate (clascoterone) is a novel androgen antagonist that is currently being analyzed in a large phase 2 clinical trial for the topical treatment of androgenetic alopecia (AGA). While the pathogenesis of AGA is still debated, the consensus is that AGA is an androgen-dependent hair disorder with strong genetic links, and that the testosterone metabolite, dihydrotestosterone (DHT), plays a causal role in its development. DHT binds to the androgen receptor (AR) in scalp dermal papilla cells (DPC) to induce AR-mediated transcription of genes that contribute to AGA in genetically predisposed individuals.\ \ Several studies have established that clascoterone is a potent antiandrogen that is well tolerated and has selective topical activity. The study described herein elucidates a potential mechanism of clascoterone in AGA. Clascoterone was found to inhibit AR-regulated transcription in a reporter cell line with similar efficacy to the 5α-reductase inhibitor, finasteride. More importantly, when compared with another direct AR antagonist, enzalutamide, clascoterone was significantly better at inhibiting IL-6 synthesis from DHT-stimulated primary cultures of human scalp DPC. Therefore, clascoterone may be an excellent candidate to be the first topical antiandrogen for treating AGA.\ \ J Drugs Dermatol. 2019;18(2):197-201. Topics: Administration, Topical; Alopecia; Androgen Receptor Antagonists; Cell Line; Cells, Cultured; Cortodoxone; Hair Follicle; Humans; Propionates; Receptors, Androgen	2019

Article

Year

Clascoterone as a novel treatment for androgenetic alopecia.

Clinical and experimental dermatology, 2020, Volume: 45, Issue:7

Topics: Alopecia; Cortodoxone; Dihydrotestosterone; Hair Follicle; Humans; Propionates; Testosterone

2020

Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro

Journal of drugs in dermatology : JDD, 2019, Feb-01, Volume: 18, Issue:2

Cortexolone 17α-propionate (clascoterone) is a novel androgen antagonist that is currently being analyzed in a large phase 2 clinical trial for the topical treatment of androgenetic alopecia (AGA). While the pathogenesis of AGA is still debated, the consensus is that AGA is an androgen-dependent hair disorder with strong genetic links, and that the testosterone metabolite, dihydrotestosterone (DHT), plays a causal role in its development. DHT binds to the androgen receptor (AR) in scalp dermal papilla cells (DPC) to induce AR-mediated transcription of genes that contribute to AGA in genetically predisposed individuals.\ \ Several studies have established that clascoterone is a potent antiandrogen that is well tolerated and has selective topical activity. The study described herein elucidates a potential mechanism of clascoterone in AGA. Clascoterone was found to inhibit AR-regulated transcription in a reporter cell line with similar efficacy to the 5α-reductase inhibitor, finasteride. More importantly, when compared with another direct AR antagonist, enzalutamide, clascoterone was significantly better at inhibiting IL-6 synthesis from DHT-stimulated primary cultures of human scalp DPC. Therefore, clascoterone may be an excellent candidate to be the first topical antiandrogen for treating AGA.\ \ J Drugs Dermatol. 2019;18(2):197-201.

Topics: Administration, Topical; Alopecia; Androgen Receptor Antagonists; Cell Line; Cells, Cultured; Cortodoxone; Hair Follicle; Humans; Propionates; Receptors, Androgen

2019